Archives seattle-genetics

by in
Entry Author Date Location
Adaptive Biotechnologies Reaches Fork in the Road. What to Charge? 04/03/13 Seattle
How to Make the Payers Pay: Join the Xconomy Event April 9 03/26/13 Seattle
Biotech for the Belt-Tightening Era: Last Chance For Early-Bird Tix 03/12/13 Seattle
Some Bold Baseball and Biotech Picks for the 2013 Season 03/11/13 National
Genentech, ImmunoGen Win FDA OK for Souped-Up Breast Cancer Drug 02/22/13 San Francisco
Blaze Bioscience Caps Off $8.5M Financing, Charges Toward Clinic 02/22/13 Seattle
Adimab Grows Up, Looks to Pay Off the VCs In Unusual Way 02/22/13 Boston
Join Us at “Biotech in the Belt-Tightening Era” April 9 in Seattle 02/14/13 Seattle
Seattle Genetics Gets $138M in First-Year Sales of Cancer Drug 02/12/13 Seattle
Companion Diagnostics for Cancer Drugs Advancing Personalized Medicine 01/31/13 Boston
Who Are Biotech’s New Go-To Investment Bankers? 11/12/12 National
Seattle Genetics, Millennium Cancer Drug Cleared in EU 10/31/12 Seattle
Seattle Genetics Gets $25M in Broader Abbott Deal 10/23/12 Seattle
Exclusive: OVP Venture Partners, NW’s Oldest VC Firm, To Shut Down 10/11/12 Seattle
Betting on Biotech to Catalyze U.S. Job Growth? Don’t Count On It 10/01/12 National
Seattle Genetics Gets $34.7M in Second-Quarter Sales of Cancer Drug 08/08/12 Seattle
U.S. Biotech Clusters Are Losing Their Anchor Tenants, and It Hurts 08/06/12 National
Actinium Advances Armed Cancer Drugs, Preps for Wall Street Debut 08/01/12 New York
Seattle Genetics, Millennium Get EU Recommendation for Lymphoma Drug 07/20/12 Seattle
Life Science Innovation NW Notes: SeaGen, NanoString, Viket, & More 07/12/12 Seattle
Gates Foundation’s Jeff Raikes To Start Off Seattle Biotech Event 07/10/12 Seattle
The Best Boring Companies in Biotech 07/09/12 National
Merck Bets $15M on Ambrx’s “Smart Bomb” Antibodies 06/18/12 San Diego
ASCO Wrap-Up: A Summary of This Week’s Cancer R&D Headlines 06/05/12 National
NanoString Nabs Ex-Seattle Genetics Exec to Lead Diagnostic Push 05/29/12 Seattle
Seattle Genetics Follows the Science, Taking on Rare Lymphoma No. 3 05/23/12 Seattle
Who’s on Biotech’s Endangered Species List? Mid-Sized Drugmakers 05/21/12 National
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies 05/16/12 National
Seattle Genetics Misses 1st Quarter Sales Estimate, But Sees $1B Future 05/08/12 Seattle
Sutro Biopharma Pulls in $16M for New Antibody Drugs 05/08/12 San Francisco
Page 2 of 9 « previous page · next page »